Groupe Hospitalier Rance Emeraude

The site is advancing precision dosing and novel biomarker‑driven approaches to improve treatment outcomes across several disease areas. Researchers are testing pharmacokinetic‑guided bevacizumab regimens, evaluating gut‑microbiome modulation with EXL01, and using advanced imaging to monitor brain radionecrosis after radiotherapy.

• Pharmacokinetic‑adjusted bevacizumab dosing in metastatic colorectal cancer
• Gut microbiome‑based EXL01 combined with immunotherapy for gastric cancer
• Imaging‑guided assessment of bevacizumab efficacy in brain radionecrosis

Groupe Hospitalier Rance Emeraude supports 33 active trials led by 23 investigators, reflecting a strong commitment to innovative diagnostic and therapeutic technologies.

A major focus is on improving survival for patients with gastrointestinal malignancies and inflammatory bowel conditions. Trials aim to enhance disease‑free survival after surgery, evaluate targeted agents for BRAF‑mutated tumors, and compare intensified chemotherapy regimens for high‑risk disease.

• Adjuvant mFOLFIRINOX versus capecitabine/gemcitabine for resected ampullary adenocarcinoma
• High‑immune infiltrate MSS colorectal cancer treated with pembrolizumab plus chemotherapy
• Neoadjuvant encorafenib and cetuximab for BRAF V600E‑mutated colon or rectal cancer

The programme also includes studies on ulcerative colitis remission and novel strategies for gastric and esophageal adenocarcinoma.

Clinical research targets autoimmune and inflammatory disorders, seeking safer and more effective biologic or small‑molecule options. Objectives include reducing disease activity, limiting long‑term immunosuppression, and improving quality of life for patients with severe disease.

• Baricitinib combined with anti‑TNF therapy for refractory rheumatoid arthritis
• Rituximab versus ocrelizumab in relapsing‑remitting multiple sclerosis
• Immunosuppression discontinuation versus maintenance in ANCA‑associated vasculitis with end‑stage renal disease
• Methotrexate versus tocilizumab for giant cell arteritis

These studies reflect a comprehensive effort to refine treatment pathways for complex immune‑mediated conditions.

Oncology trials span solid tumors and hematologic malignancies, with a focus on novel agents, maintenance strategies, and treatment de‑escalation. Researchers assess overall survival and progression‑free outcomes while exploring biomarker‑driven patient selection.

• Elranatamab plus lenalidomide versus daratumumab maintenance after autologous transplant in multiple myeloma
• Ribociclib combined with endocrine therapy as adjuvant treatment for HR+ HER2‑ negative early breast cancer
• Pembrolizumab versus rilvegostomig in first‑line PD‑L1‑high non‑small cell lung cancer
• ABP 206 compared with nivolumab in unresectable or metastatic melanoma

The portfolio also includes trials in colorectal, gastric, pancreatic, and esophageal cancers, emphasizing personalized approaches.

Research in neurological conditions concentrates on managing complications of brain metastases and refining disease‑modifying therapies for multiple sclerosis. Studies evaluate both pharmacologic and procedural interventions to preserve neurological function.

• Bevacizumab versus placebo for corticodependent brain radionecrosis after radiotherapy
• Rituximab versus ocrelizumab in active relapsing‑remitting multiple sclerosis
• Assessment of objective response in patients with brain metastases receiving combined immunotherapy

These trials aim to reduce treatment‑related toxicity while maintaining disease control in the central nervous system.

A subset of studies does not fit neatly into a single therapeutic category, encompassing rare tumor subtypes, combination regimens, and exploratory biomarker analyses. The overarching goal is to generate evidence that can inform future standard‑of‑care decisions.

• Combination of trastuzumab‑deruxtecan with capecitabine and bevacizumab for HER2‑positive metastatic colorectal cancer
• KRAS G12C inhibitor (sotorasib) plus panitumumab in advanced unresectable colorectal adenocarcinoma
• T‑cell‑engaging bispecific antibody (T‑DxD) with capecitabine and bevacizumab in gastric adenocarcinoma

These investigations reflect the site’s flexibility in addressing emerging scientific questions across disease boundaries.

Studies targeting underlying immune mechanisms explore circulating tumor DNA, immune infiltrates, and checkpoint modulation to personalize therapy. Objectives include tailoring adjuvant chemotherapy and enhancing response rates through immune activation.

• ctDNA‑guided adjuvant FOLFOX6m for stage II colon cancer with positive circulating tumor DNA
• Immune‑infiltrate‑focused pembrolizumab plus XELOX/FOLFOX in microsatellite‑stable colorectal cancer
• Evaluation of Zimberelimab and Domvanalimab combined with FOLFIRI in advanced gastric adenocarcinoma

By integrating immune profiling, the research aims to refine patient selection and improve long‑term outcomes.